These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 7943629)

  • 21. Expression and ultrastructural localization of HMB-45 antigen.
    Kikuchi A; Shimizu H; Nishikawa T
    Br J Dermatol; 1996 Sep; 135(3):400-5. PubMed ID: 8949433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
    Nasr MR; El-Zammar O
    Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An immunoperoxidase study of S-100 protein in neoplastic cells in serous effusions. Use as a marker for melanoma.
    Pinto MM
    Acta Cytol; 1986; 30(3):240-4. PubMed ID: 3521174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Desmoplastic malignant melanoma of the oral mucosa. An underrecognized diagnostic pitfall.
    Kilpatrick SE; White WL; Browne JD
    Cancer; 1996 Aug; 78(3):383-9. PubMed ID: 8697380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Desmoplastic malignant melanoma. A clinicopathologic study of 14 cases.
    Walsh NM; Roberts JT; Orr W; Simon GT
    Arch Pathol Lab Med; 1988 Sep; 112(9):922-7. PubMed ID: 3415443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p53 expression in cutaneous malignant melanoma: an immunohistochemical study of 87 cases of primary, recurrent, and metastatic melanoma.
    Barnhill RL; Castresana JS; Rubio MP; Martin MT; Idoate M; Vazquez JJ; Thor AD
    Mod Pathol; 1994 Jun; 7(5):533-5. PubMed ID: 7937717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Malignant melanoma with neuroendocrine differentiation: clinical, histological, immunohistochemical and ultrastructural features of three cases.
    Eyden B; Pandit D; Banerjee SS
    Histopathology; 2005 Oct; 47(4):402-9. PubMed ID: 16178895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tyrosinase, melan-A, and KBA62 as markers for the immunohistochemical identification of metastatic amelanotic melanomas on paraffin sections.
    Kaufmann O; Koch S; Burghardt J; Audring H; Dietel M
    Mod Pathol; 1998 Aug; 11(8):740-6. PubMed ID: 9720502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparative study of HMB-45 monoclonal antibody uptake on various benign and malignant melanocytic lesions].
    Lampert A; Thomine E; Lauret P; Hemet J
    Ann Pathol; 1993; 13(2):100-7. PubMed ID: 8363667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epithelial markers in malignant melanoma. A study of primary lesions and their metastases.
    Ben-Izhak O; Stark P; Levy R; Bergman R; Lichtig C
    Am J Dermatopathol; 1994 Jun; 16(3):241-6. PubMed ID: 7524376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Procollagen 1 and Melan-A expression in desmoplastic melanomas.
    Leinweber B; Hofmann-Wellenhof R; Kaddu S; McCalmont TH
    Am J Dermatopathol; 2009 Apr; 31(2):173-6. PubMed ID: 19318805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Desmoplastic malignant melanoma: a clinicopathologic analysis of 113 cases.
    de Almeida LS; Requena L; Rütten A; Kutzner H; Garbe C; Pestana D; Gomes MM
    Am J Dermatopathol; 2008 Jun; 30(3):207-15. PubMed ID: 18496419
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers.
    Miettinen M; Fernandez M; Franssila K; Gatalica Z; Lasota J; Sarlomo-Rikala M
    Am J Surg Pathol; 2001 Feb; 25(2):205-11. PubMed ID: 11176069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunohistochemical spectrum of malignant melanoma. The common presence of keratins.
    Miettinen M; Franssila K
    Lab Invest; 1989 Dec; 61(6):623-8. PubMed ID: 2481151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of five antibodies as markers in the diagnosis of melanoma in cytologic preparations.
    Sheffield MV; Yee H; Dorvault CC; Weilbaecher KN; Eltoum IA; Siegal GP; Fisher DE; Chhieng DC
    Am J Clin Pathol; 2002 Dec; 118(6):930-6. PubMed ID: 12472287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients.
    Garbe C; Leiter U; Ellwanger U; Blaheta HJ; Meier F; Rassner G; Schittek B
    Cancer; 2003 Apr; 97(7):1737-45. PubMed ID: 12655531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemical aid at risk stratification of melanocytic neoplasms.
    Quatresooz P; Arrese JE; Pierard-Franchimont C; Pierard GE
    Int J Oncol; 2004 Jan; 24(1):211-6. PubMed ID: 14654959
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microphthalmia transcription factor: not a sensitive or specific marker for the diagnosis of desmoplastic melanoma and spindle cell (non-desmoplastic) melanoma.
    Granter SR; Weilbaecher KN; Quigley C; Fletcher CD; Fisher DE
    Am J Dermatopathol; 2001 Jun; 23(3):185-9. PubMed ID: 11391097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Demonstration of S 100 protein in malignant melanoma of the skin. Pattern of distribution and significance for determination of tumor thickness].
    Flügge G; Rassner G
    Hautarzt; 1989 May; 40(5):290-5. PubMed ID: 2661501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemistry in surgical pathology. The case of the undifferentiated malignant neoplasm.
    Linder J
    Clin Lab Med; 1990 Mar; 10(1):59-76. PubMed ID: 2184980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.